

CB2 Insights Inc.

09:24 08 Jan 2020

CB2 Insights CEO says company is on track to profitability in 2Q

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF) CEO Prad Sekar told shareholders Wednesday that the cannabis analytics company is on track to be profitable by its fiscal second-quarter 2020.

The company's focus on execution allowed it to achieve solid revenue growth since going public in March 2019, according to Sekar.

The CEO wrote in a letter to shareholders that CB2 is on track to build and develop the industry's largest data bank of anonymized clinical data on the safety, efficacy and usage of medical cannabis-based products and delivery forms.

READ: CB2 Insights to study effects of hemp CBD on patients with anxiety in partnership with GL Brands

Toronto-based CB2 now owns and operates one of the largest multi-state networks of specialty clinics in the US, assessing nearly 100,000 patients seeking treatment. The clinic network provides immediate market access to US-based product manufacturers for clinical trial and research programs, according to Sekar.

The company also built electronic data capture and clinical data management software tools for clients such as Drug Science (Project T21), VIVO Cannabis, FCM Global, Premier Health, and My Access Clinics.

According to its most recent financials, CB2 generated year to date revenue of C\$10.3 million up to 3Q 2019.

Sekar said that that CB2's latest warrant repricing program has good support and uptake by shareholders and offered the firm the "most equitable" form of non-dilutive capital.

"We have truly transformed our operation not only to reach profitability," Sekar wrote, "but to pursue opportunities that will elevate the position of CB2 Insights as a valuable provider of data and research to stakeholders in both the medical cannabis and life science verticals."

Contact Angela at angela@proactiveinvestors.com


Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Price: 0.075

Market Cap: \$6 m

1 Year Share Price Graph



April 2019 September 2019 March 2020

Share Information

Code: CBII

Listing: CSE

52 week High Low
0.335 0.055

Sector: Cannabis

Website: cb2insights.com

Company Synopsis:

Our mission is to deliver the industry's most comprehensive, data-driven software and services - transforming the way the global cannabis industry evolves through actionable insights.

action@proactiveinvestors.com

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).